PAS
ADMA icon

Point72 Asia (Singapore)’s ADMA Biologics ADMA Stock Holding History

Point72 Asia (Singapore)’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-20,532
Closed -$230K – 928
2024
Q2 		$230K Buy
+20,532
New +$172K 0.05% 268

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Point72 Asia (Singapore)'s ADMA Position: Q3 2024 in Review

Point72 Asia (Singapore) sold out of ADMA Biologics (ADMA) in Q3 2024, closing a stake of 20,532 shares — an estimated $230K sold.

Point72 Asia (Singapore) first reported a position in ADMA in Q2 2024 and held it in 1 quarter. The position peaked at $230K in Q2 2024. 306 funds tracked by Wall St. Rank hold ADMA as of Q3 2024.

  • Point72 Asia (Singapore) reported no remaining ADMA Biologics position as of Q3 2024 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 20,532 ADMA Biologics shares in Q3 2024, an estimated $230K.
  • Point72 Asia (Singapore) first reported a position in ADMA Biologics in Q2 2024 and held it in 1 quarter.
  • Point72 Asia (Singapore)'s ADMA Biologics position peaked at $230K in Q2 2024.
  • 306 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2024.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2024, filed 14 Nov 2024.